

Please type a sign (+) inside this box ! +

PTO/SB/05 (08-00)



Approved for use through 10/31/2002. OMB 0651-0032 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required respond to a collection of information unless it displays a valid OMB control number. Attorney Docket No. PT033P1 UTILITY First Inventor PATENT APPLICATION Ruben et al. Title Four Disulfide Core Domain-Containing (FDCD) TRANSMITTAL Polynucleotides, Polypeptides, and Antibodies Express Mail Label No. Assistant Commissioner for Patents APPLICATION ELEMENTS ADDRESS TO: Box Patent Application See MPEP chapter 600 concerning utility patent appli Washington, DC 20231 1. Fee Transmittal Form (e.g., PTO/SB/17) 7. CD-ROM or CD-R in duplicate, large table or Computer (Submit an original, and a duplicate for fee processing) Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission 2. Applicant claims small entity status. (if applicable, all necessary) See 37 CFR 1.27. a. Computer Readable Form (CRF) b. Specification Sequence Listing on: 3. 🛛 Specification [Total Pages 273] i. CD-ROM or CD-R (2 copies); or (preferred arrangement set forth below)

- Descriptive title of the Invention

- Cross Reference to Related Applications ii. 🛛 paper c. Statements verifying identity of above copies Statement Regarding Fed sponsored R & D
 Reference to sequence listing, a table, or a computer program listing appendix
 Background of the Invention ACCOMPANYING APPLICATION PARTS Assignment Papers (cover sheet and document(s)) Brief Summary of the Invention
 Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) 10. 37 CFR 3.73(b) Statement Power of Attorney - Abstract of the Disclosure 4. Drawing(s) (35 U.S.C. 113) (Total Sheets Unexecuted Oath or Declaration Total Pages Information Disclosure Statement/ Form PTO/SB/08 a. Newly executed (original or copy) b. Copy from a prior application (37 CFR 1.63(d)) Copies of Citations (for continuation/divisional with Box 17 completed) 13. Preliminary Amendment i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR ' 1.63(d)(2) and 1.33(b). Return Receipt Postcard (MPEP 503) (should be specifically itemzed) Application Data Sheet. See 37 CFR 1.76. Certified copy of Priority Document(s) (if foreign priority is claimed) 17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Divisional Continuation Continuation-in-Part (CIP) of prior application No: PCT/US00/32462 Prior application information: Examine: Group/Art Unit:

For CONTINUATION OR DIVISIONAL APPS only The ensure discharge of the prior application, from which an each or destination is suppled under Box 5b, is considered a part of the disclosure of the accompanying commissions or drivened application and a berely incorporated by reference. The encorporation can only be related upon when a persona has been understantly constituted from the submatted 18. CORRESPONDENCE ADDRESS Customer Number or Bar Code Label 22195 or Correspondence address below NAME ADDRESS STATE ZIP CODE COUNTRY TELEPHONE FAX NAME (Print/Type) Kenley K Hoover Registration No. (Attorney/Agent) 40,302 SIGNATURE June 6, 2001

FEE TRANSMITTAL for FY 2001			Complete if Known						
Patent fees are subject to annual revision.									
			Application Number				Unassigned		
			Filing Date				June 6, 2001		
			First Named Inventor				Ruben et al.		
			Examiner Name						
			Group Art Unit						
Total amount of payment (\$)746.00			Attorney Docket Number				PT033	P1	
METHOD OF PAYMENT (CHECK ONE) 1. The Commissioner is hereby authorized to charge indicated			FEE CALCULATION (CONTINUED)						
fees and credit any overpayment to:			3. ADDITIONAL FEES Large Entity Small Entity						
Deposit Account 08-3425			Fee	Fee	Fee	Fee		Fee Paid	
Number Deposit Account Human Genome Sciences, Inc. Name			(\$) 130	Code 205	(\$) 65	Description Surcharge - late sheet	escription rcharge - late provisional filing fee or cover		
_	127	50	227	25		e - late provisional filing fee or cover			
✓ Charge Any Additional Fee Required Under 37 CFR §§ 1.16 and 1.17			130	139	130	Non-English spe			
			2,520	147	2,520	For filing a reque	est for ex parte reexamination		
			920	112	920		Requesting publication of SIR prior to Examiner		
Applicant claims small entity status	113	1,840	113	1,840	action Requesting publi action	ting publication of SIR after Examiner			
See 37 CFR 1.27			110	215	55		ply within first month		
			390	216	195	Extension for rep	ply within second month		
2. Payment Enclosed:			890	217	445		ply within third month		
☐ Check ☐ Credit Card ☐ Money Order ☑ Other*			1,390	218	695		oly within fourth month		
Charge any deficiencies or credit any overpayments in the fees or fee			1,890	228	945	Extension for rep	ply within fifth month		
			310	219	155	Notice of Appeal	1		
FEE CALCULATION			310	220	155		support of an appeal		
1. BASIC FILING FEE			270	221	135	Request for oral			
Large Entity Small Entity Fee	Fee Paid	138	1,510	138	1,510	Petition to institu	ate a public use proceeding		
Code (S) Code (S)	Paid								
101 710 201 355 Utility filing fee	\$710.00	140	110	240	55	Petition to revive	-unavoidable		
106 320 206 160 Design filing fee 107 490 207 245 Plant filing fee	Design filing fee Plant filing fee		1,240	241	620	Petition to revive	- unintentional		
108 710 208 355 Reissue filing fee		142	1,240	242 243	620 220	Utility issue fee (or reissue) Design issue fee			
114 150 214 75 Provisional filing fee			600	244	300	Plant issue fee			
Salvat do		122 123	130	122	130	Petitions to the C			
Subtotal (1) \$710.00			50 240	123	50		to provisional applications		
=2. EXTRA CLAIM FEES			40	481	240 40		formation Disclosure Statement patent assignment per property		
		581			40	(times number of	properties)	ł	
Extra from bek	n Paid	146	710	246	355	Filing a submissi (37 CFR 1.129(a)	on after final rejection))		
Total claims 22 -20° 2	\$36.00	149	710	249	355	For each addition CFR 1.129(b))	nal invention to be examined (37		
Indep.claims 2 - 3" 0	\$ 0.00	179	710	279	355		inued Examination (RCE)		
Multiple Dependent	s	169	190	169	900	Request for expen	dited examination of a design		
Dependent .		Other fe	e (specify)			application			
Large Entity Small Entity Fee			e (specify):						
Fee Fee Fee Fee Description Code (5) Code (5)	Description								
103 18 203 9 Claims in excess of 20			Reduced by Basic Filing Fee Paid						
102 80 202 40 Independent claims in excess of 3									
104 270 204 135 Muttiple depend 108 80 209 40 **Reissue indep	5 Mutliple dependent claim								
over original patent									
110 18 210 9 **Reissue claims in excess of 20			Subtotal (3)						
and over original patent									
Subtotal (2) (\$)746.00									
Submitted By							omplete (if applicable)		
Name (Print/Type) Kenley K Hogyer	Regist	ration N	o.: 40.3	302			301-309-8504		
Signature: Date June 6, 2001									

WARNING: Information on this form may become public. Credit card information should not

be included on this form. Provide credit card information and authorization on PTO-2888.

Burdon Hour Statement: This form is estimated to take 0.2 hours to complete. Time will very depending upon the mosts of the individual case. Any comments on the amount of true you are required to complete this form should be sent to the Chief

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Ruben et al.

Application Serial No.: Not assigned

Art Unit: Not assigned

Filed: Concurrently herewith

Examiner: Not assigned

For:

Four Disulfide Core Domain-Containing (FDCD)

Polynucleotides, Polypeptides, and Antibodies

Attorney Docket No.: PT033P1

STATEMENT UNDER 37 C.F.R. 1.821(f)

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Applicants hereby certify that the hard copy of the sequence listing being filed concurrently herewith and the enclosed computer-readable form of such sequence listing are identical.

Respectfully submitted.

Date: The 6, 2001

Kenley K. Hoover Attorney for Applicants

Reg. No. 40,302

Human Genome Sciences, Inc. 9410 Key West Avenue Rockville, Maryland 20850 Telephone: (301) 610-5771

KKH/RL/ur